伊沙夫康唑作为经验性治疗侵袭性真菌感染的非标签使用。

IF 1 Q4 PHARMACOLOGY & PHARMACY

Annales pharmaceutiques francaises Pub Date : 2024-10-24 DOI:10.1016/j.pharma.2024.10.005

Anne-Lise Bienvenu, Chloe Gasser, Sophie Ducastelle-Lepretre, Nathalie Bleyzac, Vincent Piriou, Isabelle Durieu, Sandrine Roux, Aurélien Millet, Hervé Ghesquières, Gilles Leboucher, Sylvain Goutelle

{"title":"伊沙夫康唑作为经验性治疗侵袭性真菌感染的非标签使用。","authors":"Anne-Lise Bienvenu, Chloe Gasser, Sophie Ducastelle-Lepretre, Nathalie Bleyzac, Vincent Piriou, Isabelle Durieu, Sandrine Roux, Aurélien Millet, Hervé Ghesquières, Gilles Leboucher, Sylvain Goutelle","doi":"10.1016/j.pharma.2024.10.005","DOIUrl":null,"url":null,"abstract":"Given its good tolerance and broad-spectrum, isavuconazole is increasingly used off-label as an empirical therapy of invasive fungal infections. We retrospectively reviewed isavuconazole empirical treatment during a 12-month period in four hospitals. During isavuconazole treatment (n=27), none of the patients had a mycological evidence for fungal infection, but 19% (5/27) developed liver test abnormalities without leading to isavuconazole discontinuation. Isavuconazole could be considered as an off-label empirical therapy only if patients cannot receive caspofungin or liposomal amphotericin B.","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Isavuconazole off-label use as an empirical treatment of invasive fungal infections.\",\"authors\":\"Anne-Lise Bienvenu, Chloe Gasser, Sophie Ducastelle-Lepretre, Nathalie Bleyzac, Vincent Piriou, Isabelle Durieu, Sandrine Roux, Aurélien Millet, Hervé Ghesquières, Gilles Leboucher, Sylvain Goutelle\",\"doi\":\"10.1016/j.pharma.2024.10.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Given its good tolerance and broad-spectrum, isavuconazole is increasingly used off-label as an empirical therapy of invasive fungal infections. We retrospectively reviewed isavuconazole empirical treatment during a 12-month period in four hospitals. During isavuconazole treatment (n=27), none of the patients had a mycological evidence for fungal infection, but 19% (5/27) developed liver test abnormalities without leading to isavuconazole discontinuation. Isavuconazole could be considered as an off-label empirical therapy only if patients cannot receive caspofungin or liposomal amphotericin B.\",\"PeriodicalId\":8332,\"journal\":{\"name\":\"Annales pharmaceutiques francaises\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annales pharmaceutiques francaises\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.pharma.2024.10.005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales pharmaceutiques francaises","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.pharma.2024.10.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

异武康唑具有良好的耐受性和广谱性，因此越来越多地被用作侵袭性真菌感染的非标签经验疗法。我们对四家医院 12 个月内的异武康唑经验性治疗进行了回顾性研究。在伊沙武康唑治疗期间（n=27），没有一名患者有真菌感染的真菌学证据，但有 19% 的患者（5/27）出现肝功能检测异常，但并未导致伊沙武康唑停药。只有在患者无法接受卡泊芬净或脂质体两性霉素 B 的情况下，才能考虑将异武康唑作为标签外经验疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Isavuconazole off-label use as an empirical treatment of invasive fungal infections.

Given its good tolerance and broad-spectrum, isavuconazole is increasingly used off-label as an empirical therapy of invasive fungal infections. We retrospectively reviewed isavuconazole empirical treatment during a 12-month period in four hospitals. During isavuconazole treatment (n=27), none of the patients had a mycological evidence for fungal infection, but 19% (5/27) developed liver test abnormalities without leading to isavuconazole discontinuation. Isavuconazole could be considered as an off-label empirical therapy only if patients cannot receive caspofungin or liposomal amphotericin B.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annales pharmaceutiques francaises PHARMACOLOGY & PHARMACY-

CiteScore

1.70

自引率

7.70%

发文量

期刊介绍： This journal proposes a scientific information validated and indexed to be informed about the last research works in all the domains interesting the pharmacy. The original works, general reviews, the focusing, the brief notes, subjected by the best academics and the professionals, propose a synthetic approach of the last progress accomplished in the concerned sectors. The thematic Sessions and the – life of the Academy – resume the communications which, presented in front of the national Academy of pharmacy, are in the heart of the current events.